Literature DB >> 2467090

Effects of perindopril on tissue angiotensin-converting enzyme activity demonstrated by quantitative in vitro autoradiography.

K Sakaguchi1, B Jackson, S Y Chai, F A Mendelsohn, C I Johnson.   

Abstract

Inhibition of plasma angiotensin II generation does not fully explain the chronic hypotensive effects of angiotensin-converting enzyme (ACE) inhibitors. Therefore, the pattern of tissue ACE inhibition in rats was studied after oral administration of perindopril, a new ACE inhibitor. Tissue ACE was measured by quantitative in vitro autoradiography using [125I]-351A as a radioligand and compared with plasma ACE and the pressor response to intravenous (i.v.) angiotensin I. Following oral perindopril (1 mg/kg), plasma ACE activity was acutely reduced, but recovered over 24 h. The peak concentration of plasma perindoprilic acid, the active diacid of perindopril, occurred at 1 h, and the drug was undetectable by 24 h. The pressor response to i.v. angiotensin I was inhibited by 95% at 4 h and had not fully recovered by 24 h. Four hours after oral administration of perindopril, ACE was markedly inhibited in the proximal tubules of the kidney (24% control), lung parenchyma (10%), and aortic wall (18%) (p less than 0.01). At 24 h, ACE in these tissues had only partially recovered (32-63%). ACE was also identified in vascular endothelium of organs, including the lung, kidney, and testis; in these sites, vascular ACE showed a pattern of inhibition similar to that of aortic ACE. In contrast, ACE in testicular seminiferous tubules was unaffected by perindopril. These results demonstrate a prolonged effect of ACE inhibitors on tissue ACE that may better explain the time course of these drugs than the changes in plasma ACE or plasma levels of the drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2467090     DOI: 10.1097/00005344-198812000-00013

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Authors:  R J Macfadyen; K R Lees; J L Reid
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 3.  Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients?

Authors:  F D Hobbs
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

Review 4.  Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  P A Todd; A Fitton
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

5.  Perindopril, an angiotensin converting enzyme inhibitor, in pulmonary hypertensive rats: comparative effects on pulmonary vascular structure and function.

Authors:  T K Jeffery; J C Wanstall
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

6.  Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.

Authors:  David G Levitt; Rik C Schoemaker
Journal:  BMC Clin Pharmacol       Date:  2006-01-06

7.  Angiotensin-converting enzyme inhibitors of Bothrops jararaca snake venom affect the structure of mice seminiferous epithelium.

Authors:  Carlos Alberto-Silva; Joyce M Gilio; Fernanda C V Portaro; Samyr M Querobino; Antonio C M Camargo
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2015-08-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.